[Serum concentration of HCFU and 5-FU after oral administration of HCFU in postoperative digestive cancer patients].
In an attempt to establish the optimum dose of HCFU, the effect of the presence of stomach on the absorption of HCFU and both the rise and maintenance of blood HCFU levels was evaluated in patients with gastric cancer (total gastrectomy group) and with colorectal cancer (non-gastrectomy group). The blood concentrations of HCFU fractions and 5-FU were determined in terms of pharmacokinetic parameters in these groups. The Tmax was significantly different between the two groups, with HCFU fraction and 5-FU levels that were significantly higher in the total gastrectomy group 30 minutes after administration. No differences were found in Cmax or AUC. There were no significant differences in Cmax or AUC among the various subgroups given different doses of HCFU (100, 150 and 200 mg) in either group, although dose-dependency was observed. Similar results were obtained in crossover tests. The 5-FU remained at an effective concentration of 0.05 microgram/ml, 4 hours after a single dose of 100 mg HCFU.
Kuroda
Y
Y
Dept. of Surgery I, University of Occupational and Environmental Health, School of Medicine, Kita-kyushu, Japan.
Ohkuma
R
R
Ohsato
K
K
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D003110:Colonic Neoplasms / Q000097:blood* / Q000188:drug therapy; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood* / Q000493:pharmacokinetics; D005743:Gastrectomy; D006801:Humans; D013274:Stomach Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000601:surgery
D000970:Antineoplastic Agents; C017367:carmofur; D005472:Fluorouracil